|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NR0B2 |
Gene summary for NR0B2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NR0B2 | Gene ID | 8431 |
| Gene name | nuclear receptor subfamily 0 group B member 2 | |
| Gene Alias | SHP | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q15466 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8431 | NR0B2 | S43 | Human | Liver | Cirrhotic | 2.68e-09 | -2.61e-01 | -0.0187 |
| 8431 | NR0B2 | HCC1_Meng | Human | Liver | HCC | 1.64e-64 | -4.91e-02 | 0.0246 |
| 8431 | NR0B2 | HCC2_Meng | Human | Liver | HCC | 5.54e-08 | -3.15e-01 | 0.0107 |
| 8431 | NR0B2 | cirrhotic1 | Human | Liver | Cirrhotic | 1.88e-13 | 3.70e-01 | 0.0202 |
| 8431 | NR0B2 | cirrhotic2 | Human | Liver | Cirrhotic | 1.55e-08 | 1.82e-01 | 0.0201 |
| 8431 | NR0B2 | HCC2 | Human | Liver | HCC | 3.34e-04 | 2.85e+00 | 0.5341 |
| 8431 | NR0B2 | Pt13.b | Human | Liver | HCC | 1.87e-04 | 5.60e-02 | 0.0251 |
| 8431 | NR0B2 | Pt13.c | Human | Liver | HCC | 1.96e-02 | -3.21e-01 | 0.0076 |
| 8431 | NR0B2 | S014 | Human | Liver | HCC | 2.05e-02 | 1.05e+00 | 0.2254 |
| 8431 | NR0B2 | S015 | Human | Liver | HCC | 3.04e-02 | 9.68e-01 | 0.2375 |
| 8431 | NR0B2 | S016 | Human | Liver | HCC | 4.34e-12 | 1.48e+00 | 0.2243 |
| 8431 | NR0B2 | S027 | Human | Liver | HCC | 1.81e-06 | 1.74e+00 | 0.2446 |
| 8431 | NR0B2 | S028 | Human | Liver | HCC | 3.55e-17 | 1.58e+00 | 0.2503 |
| 8431 | NR0B2 | S029 | Human | Liver | HCC | 4.38e-26 | 2.39e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000820211 | Liver | Cirrhotic | steroid metabolic process | 143/4634 | 319/18723 | 2.79e-15 | 3.18e-13 | 143 |
| GO:190495112 | Liver | Cirrhotic | positive regulation of establishment of protein localization | 135/4634 | 319/18723 | 3.20e-12 | 2.28e-10 | 135 |
| GO:19026521 | Liver | Cirrhotic | secondary alcohol metabolic process | 75/4634 | 147/18723 | 5.62e-12 | 3.91e-10 | 75 |
| GO:00082031 | Liver | Cirrhotic | cholesterol metabolic process | 70/4634 | 137/18723 | 2.59e-11 | 1.55e-09 | 70 |
| GO:00161251 | Liver | Cirrhotic | sterol metabolic process | 75/4634 | 152/18723 | 4.54e-11 | 2.61e-09 | 75 |
| GO:005122212 | Liver | Cirrhotic | positive regulation of protein transport | 126/4634 | 303/18723 | 6.85e-11 | 3.77e-09 | 126 |
| GO:000606612 | Liver | Cirrhotic | alcohol metabolic process | 141/4634 | 353/18723 | 1.57e-10 | 8.03e-09 | 141 |
| GO:000974312 | Liver | Cirrhotic | response to carbohydrate | 101/4634 | 253/18723 | 6.24e-08 | 1.92e-06 | 101 |
| GO:003428412 | Liver | Cirrhotic | response to monosaccharide | 90/4634 | 225/18723 | 2.87e-07 | 7.01e-06 | 90 |
| GO:000762312 | Liver | Cirrhotic | circadian rhythm | 84/4634 | 210/18723 | 7.04e-07 | 1.50e-05 | 84 |
| GO:000974612 | Liver | Cirrhotic | response to hexose | 86/4634 | 219/18723 | 1.30e-06 | 2.59e-05 | 86 |
| GO:009730512 | Liver | Cirrhotic | response to alcohol | 96/4634 | 253/18723 | 1.97e-06 | 3.65e-05 | 96 |
| GO:00097497 | Liver | Cirrhotic | response to glucose | 82/4634 | 212/18723 | 4.54e-06 | 7.51e-05 | 82 |
| GO:00329221 | Liver | Cirrhotic | circadian regulation of gene expression | 34/4634 | 68/18723 | 6.04e-06 | 9.74e-05 | 34 |
| GO:003110011 | Liver | Cirrhotic | animal organ regeneration | 35/4634 | 76/18723 | 4.26e-05 | 5.03e-04 | 35 |
| GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
| GO:004851111 | Liver | Cirrhotic | rhythmic process | 103/4634 | 298/18723 | 8.47e-05 | 9.19e-04 | 103 |
| GO:003109911 | Liver | Cirrhotic | regeneration | 71/4634 | 198/18723 | 3.02e-04 | 2.65e-03 | 71 |
| GO:000686911 | Liver | Cirrhotic | lipid transport | 128/4634 | 398/18723 | 4.54e-04 | 3.69e-03 | 128 |
| GO:00454711 | Liver | Cirrhotic | response to ethanol | 48/4634 | 137/18723 | 4.45e-03 | 2.35e-02 | 48 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NR0B2 | SNV | Missense_Mutation | c.157C>G | p.His53Asp | p.H53D | Q15466 | protein_coding | deleterious(0.05) | benign(0.023) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | PD | ||
| NR0B2 | insertion | Nonsense_Mutation | novel | c.551_552insTGAATTAAGTTATTGATTTTTGTAATAAAAGGTATGAAA | p.Ala184_Ala185insGluLeuSerTyrTerPheLeuTerTerLysValTerAsn | p.A184_A185insELSY*FL**KV*N | Q15466 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| NR0B2 | insertion | Frame_Shift_Ins | novel | c.550_551insAA | p.Ala184GlufsTer32 | p.A184Efs*32 | Q15466 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| NR0B2 | insertion | Nonsense_Mutation | novel | c.462_463insAATACATTGAAAATTGATAAATAAAT | p.Ser155AsnfsTer8 | p.S155Nfs*8 | Q15466 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| NR0B2 | SNV | Missense_Mutation | c.484N>C | p.Ser162Arg | p.S162R | Q15466 | protein_coding | deleterious(0) | possibly_damaging(0.845) | TCGA-EI-7002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | irinotecan+5-fluorouracilim | SD | |
| NR0B2 | SNV | Missense_Mutation | rs780173746 | c.253C>T | p.Arg85Trp | p.R85W | Q15466 | protein_coding | deleterious(0.02) | possibly_damaging(0.761) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NR0B2 | SNV | Missense_Mutation | c.292C>T | p.Leu98Phe | p.L98F | Q15466 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NR0B2 | SNV | Missense_Mutation | novel | c.515C>T | p.Thr172Ile | p.T172I | Q15466 | protein_coding | tolerated(0.11) | benign(0.241) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| NR0B2 | SNV | Missense_Mutation | rs765631987 | c.161G>A | p.Arg54His | p.R54H | Q15466 | protein_coding | tolerated(0.3) | benign(0.031) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NR0B2 | SNV | Missense_Mutation | novel | c.5N>A | p.Ser2Asn | p.S2N | Q15466 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8431 | NR0B2 | TRANSCRIPTION FACTOR BINDING, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | 252827495 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |